Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Antimicrobial agents and chemotherapy - 1 Dec 2017

Hassounah Said A, Alikhani Ahmad, Oliveira Maureen, Bharaj Simrat, Ibanescu Ruxandra-Ilinca, Osman Nathan, Xu Hong-Tao, Brenner Bluma G, Mesplède Thibault, Wainberg Mark A

Abstract excerpt

Animal models are essential to study novel antiretroviral drugs, resistance-associated mutations (RAMs), and treatment strategies. Bictegravir (BIC) is a novel potent integrase strand transfer inhibitor (INSTI) that has shown promising results against HIV-1 infection in vitro and in vivo and against clinical isolates with resistance against INSTIs. BIC has a higher genetic barrier to the development of resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 4 or More Rings

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Raltegravir Potassium

Share to Reverse Genetics

Source

Open in PubMed Open full text

Identifiers

PMID: 28923862
DOI: 10.1128/AAC.01695-17
PMCID: PMC5700299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.PMID 28923862Read ↗

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.Semantic proximity Read ↗

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.Semantic proximity Read ↗

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.Semantic proximity Read ↗

HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase MutantsSemantic proximity Read ↗

HIV drug resistance against strand transfer integrase inhibitors.Semantic proximity Read ↗

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.Semantic proximity Read ↗

High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.Semantic proximity Read ↗

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.Semantic proximity Read ↗

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.Semantic proximity Read ↗

Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer InhibitorsSemantic proximity Read ↗

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.Semantic proximity Read ↗

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.